Plm-102, a Next Generation FLT3 Inhibitor, Shows Potent Anti-Leukemic Activity on Resistance to Gilteritinib in FLT3 Mutated Acute Myeloid Leukemia

被引：0
|
作者：
Lee, Jae-Seon [1 ]
Park, Min Ji [1 ]
Sun, Ningning [1 ]
Park, Jin-Hee [1 ]
Oh, Su-jin [1 ]
Moon, Miran [1 ]
Kim, Myung Jin [1 ]
Jang, Soo Yeon [1 ]
Kim, Yong-Chul [1 ]
机构：
[1] PeLeMed, Seoul, South Korea
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-180483
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia
    Fathi, Amir T.
    Chen, Yi-Bin
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 98 (04) : 330 - 336
  • [22] NMS-03592088, a novel, potent FLT3, KIT and CSF1R inhibitor with activity in FLT3 positive acute myeloid leukemia patients with prior FLT3 inhibitor experience
    Curti, Antonio
    Rambaldi, Alessandro
    Cattaneo, Chiara
    Cairoli, Roberto
    Della Porta, Matteo
    Chiusolo, Patrizia
    Lussana, Federico
    Ubezio, Marta
    Mancini, Valentina
    Cano, Isabel
    Besliu, Carmen
    Claussen, Christian Hove
    Gatto, Rosalinda
    Crivori, Patrizia
    Colajori, Elena
    Somaschini, Alessio
    Davite, Cristina
    Isacchi, Antonella
    Ardini, Elena
    Mahnke, Lisa
    Montesinos, Pau
    CANCER RESEARCH, 2023, 83 (08)
  • [23] Discovery of SILA-123 as a Highly Potent FLT3 Inhibitor for the Treatment of Acute Myeloid Leukemia with Various FLT3 Mutations
    Wei, Tian-Hua
    Wang, Zi-Xuan
    Lu, Meng-Yi
    Xu, Yu-Jing
    Yang, Jin
    Ni, Xing-Feng
    Cheng, Yang
    Zhang, Meng-Yuan
    Liu, Jia-Chuan
    Li, Qing-Qing
    Cai, Jiao
    Chen, Zi-Jun
    Kang, Ji-Bo
    Li, Nan
    Dai, Wei-Chen
    Ding, Ning
    Yu, Yan-Cheng
    Leng, Xue-Jiao
    Xue, Xin
    Wang, Xiao-Long
    Sun, Shan-Liang
    Yang, Ye
    Li, Nian-Guang
    Shi, Zhi-Hao
    JOURNAL OF MEDICINAL CHEMISTRY, 2024,
  • [24] Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy
    Zhang, Weiguo
    Yu, Guopan
    Zhang, Hongying
    Basyal, Mahesh
    Ly, Charlie
    Yuan, Bin
    Ruvolo, Vivian
    Piya, Sujan
    Bhattacharya, Seemana
    Zhang, Qi
    Borthakur, Gautam
    Battula, Venkata L.
    Konopleva, Marina
    Rice, William G.
    Andreeff, Michael
    HAEMATOLOGICA, 2023, 108 (06) : 1500 - 1514
  • [25] Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia (vol 7, 19, 2019)
    Zhao, Juanjuan
    Song, Yongping
    Liu, Delong
    BIOMARKER RESEARCH, 2019, 7 (01)
  • [26] Incorporation of FLT3 Inhibitors Into the Treatment Regimens for FLT3 Mutated Acute Myeloid Leukemia The Case for Total Therapy
    Perl, Alexander E.
    Pratz, Keith W.
    CANCER JOURNAL, 2022, 28 (01): : 14 - 20
  • [27] Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation
    Chew, Serena
    Mackey, Melissa C.
    Jabbour, Elias
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [28] Optimizing FLT3 Inhibitor Use in Adult Acute Myeloid Leukemia with FLT3 Mutations Using Proteomics
    Magalhaes, Eduardo Sabino
    Hubner, Stefan
    Brown, Brandon D.
    Qiu, Yihua
    Kornblau, Steven M.
    BLOOD, 2023, 142
  • [29] AMG 925 Is a Dual FLT3/CDK4 Inhibitor with the Potential to Overcome FLT3 Inhibitor Resistance in Acute Myeloid Leukemia
    Li, Cong
    Liu, Liqin
    Liang, Lingming
    Xia, Zhen
    Li, Zhihong
    Wang, Xianghong
    McGee, Lawrence R.
    Newhall, Katie
    Sinclair, Angus
    Kamb, Alexander
    Wickramasinghe, Dineli
    Dai, Kang
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (02) : 375 - 383
  • [30] COMBINED INHIBITION OF HEDGEHOG AND FLT3 SIGNALLING LEADS TO EFFECTIVE ANTI-LEUKEMIC EFFECTS IN ACUTE MYELOID LEUKEMIA
    Latuske, E.
    Stamm, H.
    Klokow, M.
    Vohwinkel, G.
    Kebenko, M.
    Bokemeyer, C.
    Juecker, M.
    Fiedler, W.
    Wellbrock, J.
    HAEMATOLOGICA, 2015, 100 : 354 - 355
12345